1. I would really appreciate it if the impact analysis for this project could be improved. I don’t like the “back of the envelope” calculation that I put in the summary, but I don’t know how to improve it.
2. Will Samuel et al 2010 replicate? In other words, does the cheap and widely available antifungal drug itraconazole cause remission in Crohn’s patients? We have to find out.
3. It is worth mentioning that the main immunological biomarker of Crohn’s disease is antibodies against fungal sugars (mannan, beta-glucan and chitin). https://www.ncbi.nlm.nih.gov/pubmed/16890590 This means the efficacy of an antifungal compound for Crohn’s is plausible.
To summarize:
1. I would really appreciate it if the impact analysis for this project could be improved. I don’t like the “back of the envelope” calculation that I put in the summary, but I don’t know how to improve it.
2. Will Samuel et al 2010 replicate? In other words, does the cheap and widely available antifungal drug itraconazole cause remission in Crohn’s patients? We have to find out.
3. It is worth mentioning that the main immunological biomarker of Crohn’s disease is antibodies against fungal sugars (mannan, beta-glucan and chitin). https://www.ncbi.nlm.nih.gov/pubmed/16890590 This means the efficacy of an antifungal compound for Crohn’s is plausible.